FM
VRDN icon

Frazier Management’s Viridian Therapeutics VRDN Stock Holding History

Frazier Management’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-1,505,200
Closed -$29.8M – 30
2021
Q4 		$29.8M Hold
1,505,200
– – 2.29% 18
2021
Q3 		$24.8M Buy
+1,505,200
New +$22.1M 1.98% 14

Other funds holding VRDN

VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return

Frazier Management's VRDN Position: Q1 2022 in Review

Frazier Management sold out of Viridian Therapeutics (VRDN) in Q1 2022, closing a stake of 1,505,200 shares — an estimated $29.8M sold.

Frazier Management first reported a position in VRDN in Q3 2021 and held it in 2 quarters. The position peaked at $29.8M in Q4 2021. 73 funds tracked by Wall St. Rank hold VRDN as of Q1 2022.

  • Frazier Management reported no remaining Viridian Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Frazier Management sold 1,505,200 Viridian Therapeutics shares in Q1 2022, an estimated $29.8M.
  • Frazier Management first reported a position in Viridian Therapeutics in Q3 2021 and held it in 2 quarters.
  • Frazier Management's Viridian Therapeutics position peaked at $29.8M in Q4 2021.
  • 73 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q1 2022.

Based on Frazier Management's 13F filing for Q1 2022, filed 13 May 2022.